Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Placebo-controlled, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of An Adjuvanted Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years

Next Previous
Trial Profile

A Phase 1, Placebo-controlled, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of An Adjuvanted Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 6425090 (Primary) ; QS 21; Toxoids
  • Indications Clostridium difficile infections
  • Focus Adverse reactions
  • Acronyms QS-21 study
  • Sponsors Pfizer

    • Most Recent Events

    • 03 Sep 2021 Results assessing the safety and immunogenicity data from two clinical studies (QS-21 study NCT02052726 and toxoid-alone study NCT02117570) that evaluated the use of alternative formulations of this vaccine candidate in healthy adults, published in the Vaccine.
    • 09 Jun 2015 Planned End Date changed from 1 Jul 2015 to 1 May 2015 as per ClinicalTrials.gov record.
    • 09 Jun 2015 Planned primary completion date changed from 1 Jul 2015 to 1 May 2015 as per ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top